Summary of the impact

Novel bioluminescent bacterial biosensors developed at UWE, Bristol, and commercialised by Randox, have been used by a range of companies to demonstrate effectiveness of drugs and decontamination procedures. This has improved development processes at companies including Clavis Pharma, Purest Solutions and Dycem, leading to new manufacturing processes and quality control test methods. The biosensors are used in novel applications to give pharmacodynamic data on effectiveness of drugs and real time in-situ demonstration of effectiveness of decontamination processes. These biosensors, pioneered and developed by Vyv Salisbury's group, have been commercially adopted and used for evaluation by at least six collaborating companies.

Summary of the impact

Pre-eclampsia is a major contributor to death and disability in pregnancy. Diagnosis, based on accurate blood pressure (BP)/proteinuria determination, is limited by measurement errors and being late features of the disease. In collaboration with industry, King's College London (KCL) researchers have developed an inexpensive, accurate, simple BP device suitable for rural clinics. This device allows intervention to reduce mortality/morbidity and is currently being rolled out in a Gates Foundation project in Africa and Asia. KCL researchers have also helped the company Alere Inc. with the development of a diagnostically accurate test of placental growth factor (PlGF) in women with suspected pre-eclampsia: Alere Triage^®PlGF. This demonstrates high sensitivity, superior to current tests, and following commercialisation is being adopted internationally. Their work is additionally reflected in guidelines of international standards for BP device accuracy.

Summary of the impact

Evidence about the need for and provision of health visiting services generated through research undertaken at King's College London (KCL) has underpinned major changes in national policies for health visiting. Our findings about health visitors' practice, availability and distribution of services and effectiveness in terms of parenting/child outcomes, revealed both shortfalls in provision and opportunities for improvement and led to the development of a new caseload weighting tool and funding model for service planning. The accumulated evidence from this research helped convince the UK Government in 2010 to commit to 4,200 more health visitors by 2015 — a workforce expansion of nearly 50% — in a time of austerity and restraint elsewhere in the public sector.

Summary of the impact

Research undertaken at the Centre for Intellectual and Developmental Disabilities(CIDD), has significantly impacted upon:

1. The identification of health inequalities through improved health surveillance.
2. The development of a network of Health Facilitators linked to GP Practices to promote health screening/annual checks.
3. The development of accessible information to assist people with ID in making positive lifestyle choices and access healthcare services.
4. The development of health promotion interventions targeting secondary health conditions for people with ID.
5. The translation of this research into pre/post multi-disciplinary education.
6. The preparation of regional, national and international policy guidelines.

Summary of the impact

Dementia poses substantial public health and societal challenges for Europe as there is currently no cure, and it is estimated that 10 million Europeans will be living with the disease in 2040. Good quality information allows for decision-makers to establish appropriate health policies and target resources where they are needed and where they are effective. The ALCOVE project (2011-2013) established a European network where knowledge on dementia could be shared and developed a series of recommendations for improving dementia care and quality of life across Europe. A particular strand of research within the project on timely diagnosis of dementia led by Worcester's Association for Dementia Studies has already stimulated policy debate on this issue in the UK and elsewhere in Europe, while a `toolbox' developed through the project for those living with dementia and their carers and for health and social care professionals has informed care practice.

Summary of the impact

This case study highlights a body of research around health Research Priority Setting (RPS) that assists policy makers in effectively targeting research that has the greatest potential health benefit. Empirical research on RPS led to organizational changes, and new policies within the Cochrane Collaboration along with new training resources and new RPS exercises. A research gap on inequalities in the risk of oral cancer in the English South Asian population led to an evidence synthesis exercise being carried out by the National Institute for Health and Care Excellence (NICE) and the formulation of a new public health guideline.

Summary of the impact

Our research showed that powered rotation oscillation toothbrushes were superior to manual toothbrushes for the removal of plaque and reduction of gingivitis. This information has had impacts on national public policy, on commerce and on society.

1. The findings were used by the Department of Health in its evidence-based guidelines for preventing oral disease, which is NHS policy on preventive dentistry in England and Wales.
2. The research has also been used in worldwide marketing by Procter and Gamble (the manufacturers of the leading brand of powered rotation-oscillation toothbrush), and by another manufacturer as part of its marketing strategy for a new toothbrush.
3. Finally, as a result of this work there have been critical reviews of the research and of the toothbrushes in the media that have enabled more informed consumer choice for oral hygiene.

Summary of the impact

(1) Enhancing the awareness of (i) women of childbearing age suffering from epilepsy and prescribed new and/or older generation AEDs, and (ii) their healthcare professionals. Empowering both to make informed decisions through evidence-based practice that will reduce/prevent the risk of harm to unborn children potentially exposed to AEDs in early pregnancy.

(2) A change in the process by which GlaxoSmithKline (GSK) practices post-marketing epidemiological surveillance of the new generation AED `lamotrigine' in pregnancy.

(3) Benefit to the methodological practice of other researchers in Europe involved with AEDs and epidemiological surveillance

(4) Contribution to building European system for reproductive safety evaluation

Summary of the impact

Bladder cancer is the fifth most common form of cancer, with over 70% of cases presenting as non-muscle invasive bladder carcinomas (NMIBC). Research in the Institute of Cancer Therapeutics at the University of Bradford led to the evaluation of Apaziquone (EO9) in phase II clinical trials against high risk NMIBC in The Netherlands, and two multi-centre phase III clinical trials involving 106 centres across the USA, Canada and Europe. A total of 1,746 patients with low or high risk NMIBC received EO9 and significant reductions in the rates of recurrence at two years have been reported. Our research has impacted upon the health and welfare of patients with NMIBC.

Summary of the impact

This case study describes the reach and significance of research conducted by members of the interdisciplinary Sidney De Haan Research Centre for Arts & Health. The examples below focus on the impact of singing as a health and wellbeing intervention for adults within clinical and non-clinical populations. The research has shown that singing has had a beneficial impact on individuals and influenced fields of professional practice in health and social care in the UK and US, service delivery in the UK, and policy development in the UK through the work of the Royal Society for Public Health.